HeartBeam has announced a commercial partnership with preventive cardiology practice ClearCardio, establishing the company's first commercial customer while securing both subscription revenue and strategic investment. The agreement, structured as a Letter of Intent, outlines a staged rollout integrating HeartBeam's synthesized 12-lead ECG technology into ClearCardio's cardiac prevention programs for arrhythmia assessment.
The partnership enables patients to capture clinical-grade ECG readings from home using HeartBeam's patented cable-free 3D ECG system. This technology represents a significant advancement in remote cardiac monitoring, as it collects ECG signals from three non-coplanar directions and synthesizes them into a 12-lead ECG format traditionally only available in clinical settings. The system received FDA clearance for arrhythmia assessment in December 2024, with the 12-lead ECG synthesis software gaining clearance in December 2025.
For business leaders in the healthcare technology sector, this partnership demonstrates a viable commercialization pathway for medical AI and remote monitoring technologies. The subscription-based model provides predictable revenue streams while the strategic investment from ClearCardio indicates confidence in HeartBeam's technology and market potential. The company's broader growth strategy includes expansion into concierge care and preventive cardiology networks, suggesting a deliberate move toward value-based care models that prioritize early detection and prevention.
The implications for the healthcare industry are substantial, as this technology could reduce unnecessary emergency department visits and hospitalizations by enabling earlier detection of cardiac issues. For technology executives, HeartBeam's platform represents how AI-driven cardiac care initiatives can transform traditional medical monitoring. The company holds over 20 issued patents related to technology enablement, providing competitive barriers in the growing remote patient monitoring market.
This development comes as the company continues development of its 12-lead ECG patch monitor, potentially expanding applications beyond preventive cardiology into chronic disease management and post-operative monitoring. The ability to deliver actionable heart intelligence outside medical facilities could significantly impact healthcare costs and patient outcomes, particularly for populations with limited access to specialized cardiac care.
For investors and industry observers, the partnership validates HeartBeam's technology in a real-world clinical setting while establishing a revenue-generating customer relationship. The full details of the announcement are available in the original press release at https://ibn.fm/EDyjd. Additional information about the company's developments can be found in their newsroom at https://ibn.fm/BEAT, while comprehensive disclaimers regarding forward-looking statements and investment risks are available at http://IBN.fm/Disclaimer.
